ATE405661T1 - G protein-verwandte kinasemutanten in der essentiellen hypertonie - Google Patents

G protein-verwandte kinasemutanten in der essentiellen hypertonie

Info

Publication number
ATE405661T1
ATE405661T1 AT99902201T AT99902201T ATE405661T1 AT E405661 T1 ATE405661 T1 AT E405661T1 AT 99902201 T AT99902201 T AT 99902201T AT 99902201 T AT99902201 T AT 99902201T AT E405661 T1 ATE405661 T1 AT E405661T1
Authority
AT
Austria
Prior art keywords
essential hypertension
present
protein
related kinase
kinase mutants
Prior art date
Application number
AT99902201T
Other languages
English (en)
Inventor
Robin Felder
Pedro Jose
Original Assignee
Pedro Jose
Felder Robin A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pedro Jose, Felder Robin A filed Critical Pedro Jose
Application granted granted Critical
Publication of ATE405661T1 publication Critical patent/ATE405661T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99902201T 1998-01-12 1999-01-12 G protein-verwandte kinasemutanten in der essentiellen hypertonie ATE405661T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7119998P 1998-01-12 1998-01-12
US9827998P 1998-08-28 1998-08-28

Publications (1)

Publication Number Publication Date
ATE405661T1 true ATE405661T1 (de) 2008-09-15

Family

ID=26751950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902201T ATE405661T1 (de) 1998-01-12 1999-01-12 G protein-verwandte kinasemutanten in der essentiellen hypertonie

Country Status (9)

Country Link
US (3) US6660474B1 (de)
EP (2) EP1045918B1 (de)
JP (2) JP4652566B2 (de)
AT (1) ATE405661T1 (de)
AU (1) AU2223899A (de)
CA (1) CA2318479C (de)
DE (1) DE69939367D1 (de)
DK (1) DK1045918T3 (de)
WO (1) WO1999035279A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062490A1 (en) * 2000-10-31 2002-05-23 Koch Walter J. Hypertension
WO2002103020A1 (fr) * 2001-06-15 2002-12-27 Takeda Chemical Industries, Ltd. Nouveau gene associe a une maladie et son utilisation
EP1472540A4 (de) * 2001-12-19 2005-08-03 Millennium Pharm Inc Verfahren und zusammensetzungen für die behandlung von schmerzen und schmerzhaften störungen unter verwendung von 1465,1587, 2146, 2207, 32838, 336 und 52908
WO2005093096A1 (es) * 2004-03-29 2005-10-06 Universitat Pompeu Fabra Método y kit para la detección del riesgo de padecer hipertensión
WO2005114195A1 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 4 (grk4)
CN100465288C (zh) * 2005-08-10 2009-03-04 中国医学科学院阜外心血管病医院 检测与人类原发性高血压相关的grk4基因多态的方法
US20080268442A1 (en) * 2007-04-24 2008-10-30 Igd Intel, Llc Method and system for preparing a blood sample for a disease association gene transcript test
US8135545B2 (en) 2007-11-09 2012-03-13 Iverson Genetic Diagnostics, Inc. System and method for collecting data regarding broad-based neurotoxin-related gene mutation association
US20090125244A1 (en) * 2007-11-09 2009-05-14 Igd Intel Llc Broad-based neurotoxin-related gene mutation association from a gene transcript test
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
US9657348B2 (en) 2013-01-13 2017-05-23 Atrogi Ab Method of screening compounds for the treatment of diabetes
WO2015090350A1 (en) 2013-12-16 2015-06-25 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
CN105296488B (zh) * 2015-12-02 2018-05-01 中国人民解放军第三军医大学第三附属医院 超声微泡介导的siRNA干扰GRK4在靶向调节尿钠排泄及血压水平中的应用
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN107881226A (zh) * 2017-10-30 2018-04-06 广东药科大学 Scad基因或scad蛋白在制备防治血管重构和重大血管疾病药物中的应用
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0289121B1 (de) 1987-05-01 1995-12-27 Stratagene Mutagenesetest durch Verwendung von nicht menschlichen Lebewesen, die Test-DNS-Sequenzen enthalten
US5221778A (en) 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
JPH06507782A (ja) 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5288846A (en) 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
EP0663952A4 (de) 1992-09-11 1997-06-11 Univ California Transgene nicht-humane tiere mit zielgerichtet unterbrochenen transduktionsgenen in lymphozyten.
JPH08504766A (ja) 1992-12-14 1996-05-21 スタート テクノロジー パートナーシップ ドーパミン作動性神経系の病態の診断および治療に関するドーパミン受容体ｍＲＮＡに対してアンチセンスのオリゴヌクレオチドの投与
WO1994023049A2 (en) 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5968770A (en) 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
NO953680D0 (no) 1995-09-18 1995-09-18 Hans Prydz Cellesyklusenzymer
CN1202900A (zh) 1995-11-21 1998-12-23 Icn药品公司 用il－8和il－8受体的反义寡核苷酸抑制肿瘤生长
US5856099A (en) 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression

Also Published As

Publication number Publication date
CA2318479A1 (en) 1999-07-15
DE69939367D1 (de) 2008-10-02
EP1045918A4 (de) 2003-10-08
AU2223899A (en) 1999-07-26
WO1999035279A1 (en) 1999-07-15
EP2009109A1 (de) 2008-12-31
JP2011036253A (ja) 2011-02-24
EP1045918B1 (de) 2008-08-20
JP4652566B2 (ja) 2011-03-16
JP5340242B2 (ja) 2013-11-13
JP2002508157A (ja) 2002-03-19
US9074016B2 (en) 2015-07-07
US20050089871A1 (en) 2005-04-28
DK1045918T3 (da) 2008-12-08
US6660474B1 (en) 2003-12-09
US20100313286A1 (en) 2010-12-09
EP1045918A1 (de) 2000-10-25
CA2318479C (en) 2009-03-24

Similar Documents

Publication Publication Date Title
EP1045918A4 (de) G protein-verwandte kinasemutanten in der essentiellen hypertonie
ECSP055975A (es) Tinturas de cianina hidrofílicas, reactivas con tiol y conjugados de las mismas con biomoléculas para diagnóstico por fluorescencia
DE60005787D1 (de) Wasserlösliche rhodaminfarbstoffe und ihre konjugate
ECSP045255A (es) Cumarinas utiles como biomarcadores
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
ATE37375T1 (de) Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva.
ATE273956T1 (de) Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
TR200102800T2 (tr) Yeni bileşikler.
ATE212367T1 (de) Asymmetrische cyaninfarbstoffe als fluoreszenzlöscher
TR200102025T2 (tr) Dopamin-D3-Reseptör afinitesine sahip triazol bileşikleri
ATE445158T1 (de) Toxizitätstypisierung unter verwendung von leberstammzellen
AU3040300A (en) Fluorescent dyes for solid phase and solution phase screening
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
CA2439222A1 (en) Identification of partial agonists of the a2a adenosine receptor
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
EA200301100A1 (ru) Новые фталазиноны
WO2006047452A3 (en) Reactive 1,3’-crosslinked carbocyanines and their bioconjugates
DE69828080D1 (de) Pyrimidinderivate als markierte bindungspartner
BRPI0412716A (pt) antagonistas de receptor muscarìnico de acetilcolina
BRPI0412679A (pt) antagonistas de receptor muscarìnico de acetilcolina
EA200200732A1 (ru) Замещенные производные фенилпиперазина, их получение и применение
WO2005007090A3 (en) Inhibitors of the map kinase pathway
EA200500830A1 (ru) Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ES2185002T3 (es) Metodos y composiciones para detectar mutaciones por empalme de la deshidrogenasa de dihidro-pirimidina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties